SEHK:2509Biotechs
Qyuns Therapeutics (SEHK:2509) Stock Turns Profitable While Forecasts Cloud The Outlook
Qyuns Therapeutics came into this earnings print with a profitable twelve month track record and a stock that has drifted, with the share price down about 6.6% over the past week but still modestly higher over three months. The headline this half is simple: the company delivered H1 2026 revenue of C¥424.1m and net income of C¥203.3m, which keeps the recent profitability story intact.
The tension for you as an investor sits between those solid trailing numbers and a stock valued at roughly...